Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation
- Calvo-Lozano, Olalla
- Sierra, Miquel
- Soler, María
- Estévez, M. Carmen
- Chiscano- Camón, Luis
- Ruiz-Sanmartín, Adolfo
- Ruiz-Rodriguez, Juan Carlos
- Ferrer, Ricard
- González-López, Juan José
- Esperalba, Juliana
- Fernández-Nava, Candela
- Bueno, Leticia
- López-Aladid, Rubén
- Torres, Antoni
- Fernández-Barat, Laia
- Attoumani, Sarah
- Charrel, Remi
- Coutard, Bruno
- Lechuga, Laura M.
DOIAbstract
Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A c...
Add to ORKG